AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

Immunai already has strategic agreements with 30 pharmaceuticals companies, most of them involving much smaller financial ...

As part of the collaboration, the drugmaker will use Immunai's AI model of the immune system and machine learning for ...

Bavarian Nordic said on Thursday it has signed an agreement with the United Nations Children's Fund (UNICEF) for one million ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics.

AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late ...

Monday, AstraZeneca Plc AZN released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy.

James Gordon has given his Buy rating due to a combination of factors surrounding AstraZeneca’s position in the market and the assessment of their drug development pipeline. Firstly, despite the ...

(RTTNews) - AstraZeneca plc (AZN, AZN.L) announced on Monday that the high-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan or Dato-DXd compared to the ...

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca said: "With today's recommendation, the EGPA community in Europe is one step closer to accessing a new and ...